New Horizon Aircraft Q1FY27 Results: R&D rises to $7.4 million, net loss narrows
- R&D expenses rose to $7.4 million from $2.7 million YoY due to full-scale X7 demonstrator development
- Non-binding LOI signed with VSTAR Power Lift Aviation for up to 100 aircraft valued at ~$600 million
- Net loss narrowed to $4.1 million from $10.9 million, aided by a $3.8 million non-cash warrant gain
- Cash position remains strong at over $70 million, supporting continued engineering without immediate dilution
*this image is generated using AI for illustrative purposes only.
New Horizon Aircraft reported research and development expenses of $7.4 million for the first quarter of fiscal 2027, up from $2.7 million in the comparable period last year. The increase reflects intensified engineering efforts on the full-scale Cavorite X7 demonstrator.
The company announced a non-binding letter of intent with VSTAR Power Lift Aviation for up to 100 aircraft, valued at approximately $600 million. This agreement highlights growing demand for the X7’s hybrid-electric capabilities in emergency response and regional transport sectors.
Financial Performance
Net cash used in operations rose to $7.2 million from $2.4 million in the prior year quarter, driven by higher development spending. General and administrative expenses declined to $1.7 million from $3.2 million, primarily due to lower stock-based compensation costs.
The company reported a net loss of $4.1 million, or $0.06 per share, compared with a net loss of $10.9 million, or $0.29 per share, in the prior period. The reduction in net loss includes a $3.8 million non-cash gain from the change in fair value of warrant liabilities, versus a $5.1 million non-cash expense in the prior year.
| Metric | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| R&D Expenses | $7.4 million | $2.7 million | +$4.7 million |
| G&A Expenses | $1.7 million | $3.2 million | -$1.5 million |
| Net Cash Used in Ops | $7.2 million | $2.4 million | +$4.8 million |
| Net Loss | $4.1 million | $10.9 million | -$6.8 million |
Operational Highlights and Order Book
Management confirmed that signed letters of intent across all customers account for potential purchases of up to 200 X7s, representing more than $1 billion in indicated sales value. The VSTAR agreement adds significant weight to this pipeline, targeting medical response and regional missions in Australia.
The company maintains a strong liquidity position with over $70 million in cash. This balance sheet strength supports continued investment in development without immediate fundraising pressures. Financing activities were limited, with $0.6 million raised via the ATM program at an average rate of $2.81 (USD $2.04).
What the Numbers Show
A divergence exists between the sharp decline in headline net loss and the actual operational burn. While the net loss narrowed by $6.8 million, this was largely driven by a swing in non-cash warrant liability fair values ($3.8 million gain vs $5.1 million expense). Excluding these items, operational cash usage increased significantly as R&D spending nearly tripled. This indicates that while accounting losses improved, the underlying cost of advancing the X7 demonstrator is accelerating, consuming liquidity at a faster rate than the prior year.
How will the accelerated R&D spending impact New Horizon Aircraft's cash runway and timeline for the Cavorite X7's first flight?
What specific regulatory milestones must the X7 demonstrator achieve to convert the VSTAR letter of intent into a binding purchase agreement?
Given the $70 million cash position, what are the company's strategic plans for future capital raises once the ATM program is exhausted?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
